Skip to main content
SpringerLink
Log in

Ulipristal Acetate: a Novel Option for the Medical Management of Symptomatic Uterine Fibroids

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Fibroids, the most common tumor in women of reproductive age, impact negatively on women’s health and quality of life, and have significant cost implications for their management. The current mainstay treatments are surgical (myomectomy and hysterectomy) and more recently radiological (UAE and focused ultrasound surgery). Hysterectomy is curative but precludes future fertility, whereas the impact of the other treatments on reproduction is uncertain. With women in Western societies deferring childbearing to their 30s and 40s, when fibroids are most symptomatic, there is a pressing need for a uterus-sparing medical therapy that is cheap, effective, and enhances reproductive potential. Serendipity and meticulous translational research has shown that progesterone augments fibroid proliferation, raising the possibility that progesterone receptor modulators could inhibit fibroid growth; this research has culminated in the emergence of ulipristal acetate (UA), a first-in-class, oral selective progesterone receptor modulator (SPRM) that has successfully completed phase III clinical trials. It has been licensed in Western Europe for short-term clinical use prior to surgery, and has shown efficacy with a significant reduction in uterine bleeding, fibroid volume, and improved quality of life, without the side effects associated with other medications such as gonadotropin-releasing hormone (GnRH) agonists. As with all new medicines, there are concerns surrounding UA, not least its effect on the endometrium and the long-term impact on general health and reproduction. Research to date has tended to be industry led, and therefore, there is a need for researcher/clinician-led studies to address the wider issues concerning SPRMs. UA may not turn out to be the “Holy Grail” of medical therapy in the treatment of symptomatic uterine fibroids, but it has rightly given cause for a huge optimism. Further laboratory and clinical research into PRMs and related compounds will no doubt lead to more refined medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wise LA, Palmer JR, Stewart EA, Rosenberg L. Agespecific incidence rates for self-reported uterine leiomyomata in the Black Women’s Health Study. Obstet Gynecol. 2005;105:563–568.

    Article  PubMed  Google Scholar 

  2. Walker WJ, Barton-Smith P. Long-term followup of uterine artery embolisation — an effective alternative in the treatment of fibroids. Br J Obstet Gynaecol. 2006;113:464–468.

    Article  CAS  Google Scholar 

  3. Seinera P, Arisio R, Decko A, Farina C, Crana F. Laparoscopic myomectomy: indications, surgical technique and complications. Human Reprod. 1997;12:1927–1930.

    Article  CAS  Google Scholar 

  4. Davies A, Hart R, Magos AL. The excision of uterine fibroids by vaginal myomectomy: a prospective study. Fertil Steril. 1999;71:961–964.

    Article  PubMed  CAS  Google Scholar 

  5. Spies JB, Cooper JM, Worthington-Kirsch R, Lipman JC, Mills BB, Benenati JF. Outcome of uterine embolization and hysterectomy for leiomyomas: results of a multi-centre study. Am J Obstet Gynecol. 2004;191:22–31.

    Article  PubMed  Google Scholar 

  6. Hindley J, Gedroyc WMW, Regan L, et al. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am J Roentgenol. 2004;183:1713–1719.

    PubMed  Google Scholar 

  7. Carpenter TT, Walker WJ. Pregnancy following uterine artery embolisation for symptomatic fibroids: a series of 26 completed pregnancies. BJOG. 2005;112:321–325.

    Article  PubMed  CAS  Google Scholar 

  8. National Institute for Clinical Excellence. Guide to the methods of technology appraisal (ref. N0515). London: National Institute for Clinical Excellence, April 2004.

    Google Scholar 

  9. Wilson EA, Yang F, Rees ED. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissue. Obstet Gynecol. 1980;55:20–24.

    PubMed  CAS  Google Scholar 

  10. Tamaya T, Fujimoto J, Okada H. Comparison of cellular levels of steroid receptors in uterine leiomyomas and myometrium. Acta Gynaecol Scand. 1985;64:307–309.

    Article  CAS  Google Scholar 

  11. Talaulikar VS, Belli A, Manyonda I. GnRH agonists: do they have a place in the modern management of fibroid disease? J Obstet Gynecol India. In Press.

  12. Dubuisson JB, Fauconnier A, Fourchotte V, Babaki-Fard K, Coste J, Chapron C. Laparoscopic myomectomy: predicting the risk of conversion to an open procedure. Human Reprod. 2001;16:1726–1731.

    Article  CAS  Google Scholar 

  13. Campo S, Garcea N. Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophinreleasing hormone analogues. Human Reprod. 1999;14:44–48

    Article  CAS  Google Scholar 

  14. Vercellini P, Maddalena S, Giorgi OD, Aimi G, Crosignani PG. Abdominal myomectomy for infertility: a comprehensive review. Human Reprod. 1998;13:873–879.

    Article  CAS  Google Scholar 

  15. Fauconnier A, Chapron C, Babaki-Fard K, Dubuisson J-B. Recurrence of leiomyomata after myomectomy. Hum Reprod Update. 2000;6:595–602.

    Article  PubMed  CAS  Google Scholar 

  16. Lethaby A, Vollenhoven B. Fibroids (uterine myomatosis, leiomyomas). Clin Evid. 2002;7:1666–1678.

    PubMed  Google Scholar 

  17. Lähteenmäki P, Haukkamaa M, Puolakka J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as an alternative to hysterectomy. BMJ. 1998;316:1122–1126.

    Article  PubMed  Google Scholar 

  18. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol. 2009;21:318–324.

    Article  PubMed  Google Scholar 

  19. Maruo T, Matsuo H, Samoto T, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids. 2000;65:585–592.

    Article  PubMed  CAS  Google Scholar 

  20. Maruo T. Translational research in women’s health: From bedside to bench and from bench to bedside. Int J Gynecol Obstet. 2010;109:83–84.

    Article  Google Scholar 

  21. Ohara N, Morikawa A, Chen W, et al. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod Sci. 2007;14(Suppl.): 20–27.

    Article  PubMed  CAS  Google Scholar 

  22. Xu Q, Ohara N, Liu J, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod. 2008;14:181–191.

    Article  PubMed  CAS  Google Scholar 

  23. Yoshida S, Ohara N, Xu Q, et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med. 2010;28:260–273.

    Article  PubMed  CAS  Google Scholar 

  24. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetr Gynecol. 2008;111:1129–1136.

    Article  CAS  Google Scholar 

  25. Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril. 2011;95:767–772. 1–2.

    Article  PubMed  CAS  Google Scholar 

  26. Donnez J, Tatarchuk TF, Bouchard P, et al.; PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409–420.

    Article  PubMed  CAS  Google Scholar 

  27. Donnez J, Tomaszewski J, Vázquez F, et al; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366:421–432.

    Article  PubMed  CAS  Google Scholar 

  28. Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update. 2007;13:567–580.

    Article  PubMed  Google Scholar 

  29. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21:591–598.

    Article  PubMed  CAS  Google Scholar 

  30. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamicpituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007;92:3582–3589.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics & Gynaecology, St. George’s Hospital and University of London, Cranmer Terrace, London, SW17 0RE, UK

    Vikram S. Talaulikar & Isaac T. Manyonda

Authors
  1. Vikram S. Talaulikar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isaac T. Manyonda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Isaac T. Manyonda.

Additional information

To view enhanced content go to www.advancesintherapy.com

Rights and permissions

Reprints and permissions

About this article

Cite this article

Talaulikar, V.S., Manyonda, I.T. Ulipristal Acetate: a Novel Option for the Medical Management of Symptomatic Uterine Fibroids. Adv Therapy 29, 655–663 (2012). https://doi.org/10.1007/s12325-012-0042-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-012-0042-8

Keywords

Search

Navigation